Cell and Gene Therapy Reports Highlight Market Growth and Industry Tracking
Research and Markets added two cell and gene therapy publications, including a tools and reagents market report forecasting growth from $12 billion in 2025 to $19.8 billion by 2030. The reports track approvals, financing, deals, and manufacturing developments.
Research and Markets has added two cell and gene therapy publications to its offering, including a global tools and reagents market report and the twice-monthly Cell and Gene Therapy Business Outlook. The global market for cell and gene therapy tools and reagents is projected to rise from $12 billion in 2025 to $19.8 billion by 2030, reflecting a compound annual growth rate of 10.6%. The Business Outlook publication tracks market sizing and forecasting, financing, recent deals, and developments in cell and gene therapy manufacturing equipment and supplies.
In 2024, regulatory approvals reached a milestone, with the FDA, NMPA, EMA, and PMDA all endorsing thirteen novel CGTs. Developments included the inaugural CRISPR therapy, the first MRI-guided intracranial AAV delivery gene therapy, and a tumor infiltration lymphocyte therapy.
The tools and reagents report said market dynamics suggest that increasing clinical and commercial activities will propel demand forward. Product categories include vectors, GMP proteins, bioreactors, and more, while applications span cancer and rare diseases among other conditions. The report examines regulatory conditions, reimbursement scenarios, and emerging environmental, social, and corporate governance trends, and profiles companies including Thermo Fisher Scientific, Cytiva, Merck KGaA, Miltenyi Biotec, and Sartorius AG.
The twice-monthly Cell and Gene Therapy Business Outlook will offer market sizing and forecasting of CAGT markets, track who is getting financed and the companies behind the financing, and analyze financing trends on a regular basis. Each issue's Recent Deals Table tracks important deals between stem cell companies as well as tech transfers, partnerships, mergers, distribution and other activities with companies outside the industry. The publication will also report on developments, product launches and deals relating to makers of cell and gene therapy manufacturing equipment and supplies.